From the AGA Journals

New Associations Identified Between IBD and Extraintestinal Manifestations


 

Considering Target Therapies

As medicine becomes more specialized, physicians should remember to consider the whole patient while choosing treatment strategies.

“Sometimes doctors wear blinders to the whole person, and it’s important to be aware of a holistic approach, where a gastroenterologist also asks about potential joint inflammation or a rheumatologist asks about bowel inflammation,” said David Rubin, MD, AGAF, chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, Chicago.

Dr. Rubin, who wasn’t involved with this study, has researched and published on EIMs in IBD. He and colleagues analyzed the prevalence, pathophysiology, and clinical presentation of EIMs to better understand possibilities for disease management.

Dr. David T. Rubin, University of Chicago

Dr. David T. Rubin

“As we’ve gotten a better understanding of the immune system, we’ve learned that an EIM can sometimes provide a clue to the treatment we might use,” he said. “Given a similar amount of bowel inflammation, if one patient also has joint pain and another doesn’t, we might choose different treatments based on the immune pathway that might be involved.”

In future studies, researchers may consider whether these genetic or serologic markers could predict EIM manifestation before it occurs clinically, Dr. Rubin said. He and colleagues are also studying the links between IBD and mental health associations.

“So far, we don’t have a blood test or biopsy test that tells you which treatment is more or less likely to work, so we need to think carefully as clinicians and look to other organ systems for clues,” he said. “It’s not only more efficient to pick a single therapy to treat both the skin and bowel, but it may actually be more effective if both have a particular dominant pathway.”

The study was supported by internal funds from the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute. Several authors reported consultant roles or other associations with pharmaceutical companies. Dr. Rubin reported no relevant disclosures.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Large study reaffirms rare risk of TNF inhibitor–induced psoriasis in patients with RA, IBD
MDedge Rheumatology
Doctors urge screening for autoimmune disorders for patients with celiac disease
MDedge Rheumatology
Celiac disease linked to higher risk for rheumatoid arthritis, juvenile idiopathic arthritis
MDedge Rheumatology
First Humira biosimilar launches in U.S.
MDedge Rheumatology
FDA approves new formulation of Hyrimoz adalimumab biosimilar
MDedge Rheumatology
Clinical Practice Update: Alpha-gal syndrome often causes GI issues without anaphylaxis, skin changes
MDedge Rheumatology
Multiple successive biologic to biosimilar switches deemed safe and effective
MDedge Rheumatology
Humira biosimilars: Five things to know
MDedge Rheumatology
Are Direct-to-Consumer Microbiome Tests Clinically Useful?
MDedge Rheumatology
Spondyloarthritis Screening Study Finds ‘High Burden of Need’ in Patients With Inflammatory Bowel Disease
MDedge Rheumatology